STE Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 12.99% compared to STERIS Plc (Ireland)'s net margin of 12.68%. STERIS Plc (Ireland)'s return on equity of 10.4% beat Boston Scientific Corp.'s return on equity of 12.55%.

STERIS Plc (Ireland) has a consensus price target of $281.25, signalling upside risk potential of 13.82%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 40.85%. Given that Boston Scientific Corp. has higher upside potential than STERIS Plc (Ireland), analysts believe Boston Scientific Corp. is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.030, which suggesting that the stock is 3.006% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 1%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. STERIS Plc (Ireland)'s net income of $194.4M is lower than Boston Scientific Corp.'s net income of $670M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 34.19x while Boston Scientific Corp.'s PE ratio is 38.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.19x versus 5.54x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Edwards Lifesciences Corp. has a net margin of 12.99% compared to STERIS Plc (Ireland)'s net margin of 4.09%. STERIS Plc (Ireland)'s return on equity of 10.4% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.

STERIS Plc (Ireland) has a consensus price target of $281.25, signalling upside risk potential of 13.82%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $96.50 which suggests that it could grow by 17.06%. Given that Edwards Lifesciences Corp. has higher upside potential than STERIS Plc (Ireland), analysts believe Edwards Lifesciences Corp. is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.030, which suggesting that the stock is 3.006% more volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.133%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 1%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. STERIS Plc (Ireland)'s net income of $194.4M is higher than Edwards Lifesciences Corp.'s net income of $64.2M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 34.19x while Edwards Lifesciences Corp.'s PE ratio is 44.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.19x versus 7.96x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic Plc has a net margin of 12.99% compared to STERIS Plc (Ireland)'s net margin of 12.75%. STERIS Plc (Ireland)'s return on equity of 10.4% beat Medtronic Plc's return on equity of 9.84%.

STERIS Plc (Ireland) has a consensus price target of $281.25, signalling upside risk potential of 13.82%. On the other hand Medtronic Plc has an analysts' consensus of $111.77 which suggests that it could grow by 13.35%. Given that STERIS Plc (Ireland) has higher upside potential than Medtronic Plc, analysts believe STERIS Plc (Ireland) is more attractive than Medtronic Plc.

STERIS Plc (Ireland) has a beta of 1.030, which suggesting that the stock is 3.006% more volatile than S&P 500. In comparison Medtronic Plc has a beta of 0.709, suggesting its less volatile than the S&P 500 by 29.108%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 1%. Medtronic Plc offers a yield of 2.87% to investors and pays a quarterly dividend of $0.71 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Medtronic Plc pays out 77.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are smaller than Medtronic Plc quarterly revenues of $9B. STERIS Plc (Ireland)'s net income of $194.4M is lower than Medtronic Plc's net income of $1.2B. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 34.19x while Medtronic Plc's PE ratio is 27.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.19x versus 3.58x for Medtronic Plc. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband, Inc. has a net margin of 12.99% compared to STERIS Plc (Ireland)'s net margin of -1118.87%. STERIS Plc (Ireland)'s return on equity of 10.4% beat Nutriband, Inc.'s return on equity of -164.64%.

STERIS Plc (Ireland) has a consensus price target of $281.25, signalling upside risk potential of 13.82%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 245.62%. Given that Nutriband, Inc. has higher upside potential than STERIS Plc (Ireland), analysts believe Nutriband, Inc. is more attractive than STERIS Plc (Ireland).

STERIS Plc (Ireland) has a beta of 1.030, which suggesting that the stock is 3.006% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.886, suggesting its more volatile than the S&P 500 by 88.601%.

STERIS Plc (Ireland) has a quarterly dividend of $0.63 per share corresponding to a yield of 1%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. STERIS Plc (Ireland) pays 35.14% of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend. STERIS Plc (Ireland)'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

STERIS Plc (Ireland) quarterly revenues are $1.5B, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. STERIS Plc (Ireland)'s net income of $194.4M is higher than Nutriband, Inc.'s net income of -$3.9M. Notably, STERIS Plc (Ireland)'s price-to-earnings ratio is 34.19x while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for STERIS Plc (Ireland) is 4.19x versus 21.66x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.